Lindbrook Capital, LLC Verve Therapeutics, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 821 shares of VERV stock, worth $6,083. This represents 0.0% of its overall portfolio holdings.
Number of Shares
821
Previous 1,163
29.41%
Holding current value
$6,083
Previous $5,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VERV
# of Institutions
183Shares Held
73.3MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$91.5 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$49.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$36.8 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$31.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$29.7 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $444M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...